Israeli back pain treatment device developer Nervomatrix has reported success in a randomized controlled study conducted at Belgium's Free University of Brussels using its low back pain system. The study evaluated targeted hyper-stimulation therapy.
Founded in 2007 at the Targetech Innovation Center in Netanya, Nervomatrix is already selling its systems in the US and Europe. The Belgian study was conducted on 28 patients divided into intervention and controlled groups. The intervention group underwent a full treatment while the controlled group underwent a treatment including the scan and targeting process but excluding the actual application of the hyper-stimulation pulses. Study results demonstrate significant difference between intervention and controlled groups. The protocol includes a series of 6 treatments during 3 weeks. The difference between groups is becoming significant following the fourth treatment.
Nervomatrix said that the similar results achieved during the first single arm study completed in 2010, which also showed significant pain relief after the fourth treatment, significantly strengthen the positive outcome.
At the beginning of the technology design stages, the company intended to base its targeting algorithms on acupuncture maps. As the design process progressed and during the buildup of the first prototype, the company has abandoned these resources and developed an independent algorithm for locating and targeting pain trigger points based on electrical properties of the skin.
Nervomatrix raised $4.7 million in 2011. The company is managed by Ori Kanner and operates commercially through its two fully owned subsidiaries in the US and Belgium. The company has sold 43 systems, mostly in the US.
Published by Globes [online], Israel business news - www.globes-online.com - on August 10, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015